Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
4118 | 1768 | 48.2 | 94% |
Classes in level above (level 2) |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | JNK | Author keyword | 39 | 13% | 17% | 294 |
2 | MKK4 | Author keyword | 34 | 59% | 2% | 38 |
3 | JNK3 | Author keyword | 28 | 62% | 2% | 29 |
4 | MKK7 | Author keyword | 25 | 66% | 1% | 23 |
5 | MIXED LINEAGE KINASE | Author keyword | 21 | 71% | 1% | 17 |
6 | C JUN N TERMINAL KINASE | Author keyword | 19 | 16% | 6% | 105 |
7 | MIXED LINEAGE KINASE 3 MLK3 | Author keyword | 17 | 100% | 0% | 8 |
8 | CEP 1347 | Author keyword | 15 | 67% | 1% | 14 |
9 | MLK3 | Author keyword | 15 | 62% | 1% | 16 |
10 | JNK2 | Author keyword | 15 | 56% | 1% | 18 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | JNK | 39 | 13% | 17% | 294 | Search JNK | Search JNK |
2 | MKK4 | 34 | 59% | 2% | 38 | Search MKK4 | Search MKK4 |
3 | JNK3 | 28 | 62% | 2% | 29 | Search JNK3 | Search JNK3 |
4 | MKK7 | 25 | 66% | 1% | 23 | Search MKK7 | Search MKK7 |
5 | MIXED LINEAGE KINASE | 21 | 71% | 1% | 17 | Search MIXED+LINEAGE+KINASE | Search MIXED+LINEAGE+KINASE |
6 | C JUN N TERMINAL KINASE | 19 | 16% | 6% | 105 | Search C+JUN+N+TERMINAL+KINASE | Search C+JUN+N+TERMINAL+KINASE |
7 | MIXED LINEAGE KINASE 3 MLK3 | 17 | 100% | 0% | 8 | Search MIXED+LINEAGE+KINASE+3+MLK3 | Search MIXED+LINEAGE+KINASE+3+MLK3 |
8 | CEP 1347 | 15 | 67% | 1% | 14 | Search CEP+1347 | Search CEP+1347 |
9 | MLK3 | 15 | 62% | 1% | 16 | Search MLK3 | Search MLK3 |
10 | JNK2 | 15 | 56% | 1% | 18 | Search JNK2 | Search JNK2 |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | N TERMINAL KINASE | 62 | 13% | 26% | 460 |
2 | JNK | 60 | 19% | 16% | 286 |
3 | ZIPPER BEARING KINASE | 29 | 63% | 2% | 29 |
4 | MKK4 | 25 | 77% | 1% | 17 |
5 | MIXED LINEAGE KINASE 3 | 25 | 71% | 1% | 20 |
6 | JUN NH2 TERMINAL KINASE | 25 | 15% | 9% | 152 |
7 | NH2 TERMINAL KINASE | 24 | 33% | 3% | 60 |
8 | CEP 1347 KT7515 | 22 | 68% | 1% | 19 |
9 | MAP KINASES | 22 | 11% | 11% | 193 |
10 | MLK3 | 17 | 100% | 0% | 8 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
JNK signaling in apoptosis | 2008 | 345 | 70 | 53% |
Signal transduction by the JNK group of MAP kinases | 2000 | 2511 | 131 | 46% |
JNK signalling in cancer: in need of new, smarter therapeutic targets | 2014 | 14 | 127 | 58% |
Nuclear and cytosolic JNK signalling in neurons | 2014 | 14 | 190 | 53% |
MAMMALIAN MAPK SIGNAL TRANSDUCTION PATHWAYS ACTIVATED BY STRESS AND INFLAMMATION: A 10-YEAR UPDATE | 2012 | 187 | 331 | 28% |
Role of JNK activation in apoptosis: A double-edged sword | 2005 | 309 | 55 | 65% |
The c-jun kinase/stress-activated pathway: Regulation, function and role in human disease | 2007 | 170 | 95 | 62% |
The bottleneck of JNK signaling: Molecular and functional characteristics of MKK4 and MKK7 | 2011 | 38 | 115 | 73% |
Mitogen-activated protein kinases in apoptosis regulation | 2004 | 637 | 191 | 33% |
Targeting JNK for therapeutic benefit: From JuNK to gold? | 2003 | 382 | 79 | 58% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | INVITROGEN DISCOVERY SERV | 8 | 100% | 0.3% | 5 |
2 | MOL THER EUT DRUG DISCOVERY | 4 | 75% | 0.2% | 3 |
3 | NEURONAL DEATH NEUROPROTECT | 4 | 75% | 0.2% | 3 |
4 | PROGRAM MOL SIGNAL TRANSDUCT | 3 | 29% | 0.6% | 10 |
5 | BIOL NEURODEG DISORDERS | 3 | 100% | 0.2% | 3 |
6 | LEAD FINDING DRUG DISPOSIT SAFETY EVALUAT | 2 | 38% | 0.3% | 5 |
7 | CELL CYCLE REGULAT | 2 | 20% | 0.6% | 11 |
8 | CARDIOVASC DISCOVERY | 2 | 44% | 0.2% | 4 |
9 | LIFE PHARMACEUT | 2 | 67% | 0.1% | 2 |
10 | MARKEY MOL MED PROGRAM | 2 | 67% | 0.1% | 2 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000146613 | MK2//MAPKAP K2//MK5 |
2 | 0.0000139913 | ASK1//PP5//APOPTOSIS SIGNAL REGULATING KINASE 1 |
3 | 0.0000139780 | STE20 LIKE KINASE//MAP4K4//STE20 |
4 | 0.0000128290 | KSR1//PEA 15//IST ENDOCRINOL ONCOL SPERIMENTALE GAETANO SALVA |
5 | 0.0000122288 | ERK5//MEK5//EXTRACELLULAR SIGNAL REGULATED KINASE 5 ERK5 |
6 | 0.0000110731 | MKP 1//MAP KINASE PHOSPHATASE//DUAL SPECIFICITY PHOSPHATASE |
7 | 0.0000083198 | ATF3//ATF5//ACTIVATING TRANSCRIPTION FACTOR 3 |
8 | 0.0000079868 | FRA 1//JUN//V JUN |
9 | 0.0000079652 | RAF//RAF 1//LEO JENKINS CANC |
10 | 0.0000070595 | CARDIAC MED SECT//NHLI CARDIAC MED//BIOMED SCI MOL PATHOL |